Inresa Arzneimittel and Flynn Pharma have entered into an agreement to distribute Innocoll's CollaGuard in the UK and Germany respectively.

CollaGuard is a transparent bioresorbable film made up of 100% type I collagen and is developed using the company’s proprietary CollaFilm technology.

CollaGuard is used to prevent postoperative adhesions in patients following abdominopelvic laparotomy or laparoscopy.

Innocoll said the product is non-tacky and can be easily rolled for insertion through a trocar when implanted laparoscopically.

CollaGuard is available in various sizes up to 20 x 30 cm; it may be cut and sutured if required.

Innocoll president and CEO Michael Myers said they are pleased to announce these partnerships for two of the key markets in the EU and they look forward to a successful launch of CollaGuard.

Flynn and Inresa director David Walters said they are delighted to be working with Innocoll on this product which is consistent with, and complementary to, their model of adding products for the secondary healthcare markets.

Innocoll develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx, CollaFilm, DermaSil, CollaPress and Liquicoll.